GlassScriptPhysician profile
Adam P Taylor
NPI 1376098335
$978.64
in general payments reported to CMS, 2019-2025
26 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $44.20 · 2023: $211 · 2024: $216 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $110.84 | 2024 | |
| Novo Nordisk INC | $104.14 | 2022-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $99.85 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $94.35 | 2021-2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $85.27 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.04 | 2025 | Caplyta |
| Exact Sciences Corporation | $53.28 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $42.69 | 2023-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $35.63 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $33.63 | 2025 | Capvaxive |
| Resmed Corp | $22.67 | 2025 | |
| Radius Health, INC. | $21.42 | 2025 | Tymlos |
| Mayne Pharma Commercial LLC | $18.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.34 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.71 | 2023 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $16.35 | 2023 | Inspire |
| Boston Scientific Corporation | $16.02 | 2023 | Watchman Flx |
| Xeris Pharmaceuticals, INC. | $15.31 | 2023 | Gvoke Hypopen |
| Mylan Specialty L.P. | $15.03 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.13 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $14.13 | 2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $13.62 | 2025 | Voquezna |
| Ardelyx, INC. | $13.55 | 2024 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $13.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.81 | 2021 | |
| Amgen INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.